A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Clinical Trial ID NCT02256436

Rank	Title	Journal	Year	PubWeight™‹?›
1	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	N Engl J Med	2017	4.67
2	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
3	Muscle-invasive urothelial bladder cancer: an update on systemic therapy.	Ther Adv Urol	2015	0.98
4	Targeted therapies in bladder cancer: an overview of in vivo research.	Nat Rev Urol	2015	0.94
5	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.	Urol Oncol	2016	0.86
6	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.	Bladder Cancer	2016	0.79
7	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.	Clin Cancer Res	2015	0.78
8	Challenges and future perspectives of T cell immunotherapy in cancer.	Immunol Lett	2015	0.78
9	Immunobiology and immunotherapy in genitourinary malignancies.	Ann Transl Med	2016	0.78
10	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.	Clin Genitourin Cancer	2015	0.75
11	Systemic therapy for bladder cancer finally comes into a new age.	Future Oncol	2016	0.75
12	Clinical Trials Corner.	Bladder Cancer	2015	0.75